Do you have to try metformin before Mounjaro?

Yes for type 2 diabetes: Kansas Medicaid requires a documented trial of metformin of at least 90 days, or a documented reason it can't be used (["contraindication", "combination_with_high_a1c"]).

How long does a Mounjaro approval last with Kansas Medicaid?

Initial approvals last 6 months.

What does Kansas Medicaid require to renew Mounjaro?

Improvement in A1C and Renewal requires either: (1) reduction of HbA1c of at least 1% since the last approval, OR (2) achievement or maintenance of therapeutic HbA1c goal as specified on the initial request. Renewal duration is 12 months if at HbA1c goal, or 6 months if not at goal but at least 1% further reduction. Age and dosing limits must still be met.

How current is this information?

This page reflects Kansas Medicaid's written policy as of April 16, 2025, last verified against the source document on June 4, 2026.

Kansas Medicaid

Does Kansas Medicaid cover Mounjaro?

Quick answer · Type 2 Diabetes

Kansas Medicaid covers Mounjaro for type 2 diabetes with prior authorization on Medicaid.

Medicaid: Covered with requirements. Trial of metformin for at least 90 days, or a documented reason it can't be used (["contraindication", "combination_with_high_a1c"])

Last verified June 4, 2026. Policy effective April 16, 2025. Source: Diabetes-Mellitus-Type-2-Agents-PDF. How we verify this data →

Check your card for your exact plan →

Mounjaro for Type 2 Diabetes

What Kansas Medicaid requires, by plan type. Open this indication on its own page →

Medicaid

Covered with requirements

What you need to qualify

Age 18 and older
Trial of metformin for at least 90 days, or a documented reason it can't be used (["contraindication", "combination_with_high_a1c"])
Lab results confirming eligibility

Qualification pathways

You can qualify through any one of these.

Glycemic control in T2DM

All of:

Diagnosis of T2DM
Age >= 18 years
Prescriber provides prespecified HbA1c goal of 6.5%, 7.0%, or 8.0%
Baseline HbA1c obtained within past 6 months that is greater than the prespecified goal
Dose does not exceed 15 mg SQ weekly
Patient is not currently on a DPP-4 inhibitor
Preferred PDL drug trial completed unless non-preferred PDL PA criteria met

Plus any one of:

Adequate trial of generic metformin IR or metformin ER for at least 90 consecutive days in the past 120-day period
Prescribed generic metformin IR or ER concurrently with requested drug AND HbA1c >= 1.5% above prespecified goal
Contraindication to metformin

Documentation to bring

Prescriber-specified HbA1c goal (6.5%, 7.0%, or 8.0%)
Baseline HbA1c lab result obtained within the past 6 months showing value greater than the prespecified goal
Documentation of metformin trial (>=90 consecutive days in past 120 days), concurrent metformin prescription with HbA1c >=1.5% above goal, or contraindication to metformin
Confirmation patient is not currently on a DPP-4 inhibitor
Documentation that preferred PDL drug was tried or reason for non-preferred PA criteria

Quantity limits

2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, 15mg — Max 15 mg SQ once weekly

Approval and renewal

Initial approval: 6 months
To renew, the plan looks for improvement in A1C and Renewal requires either: (1) reduction of HbA1c of at least 1% since the last approval, OR (2) achievement or maintenance of therapeutic HbA1c goal as specified on the initial request. Renewal duration is 12 months if at HbA1c goal, or 6 months if not at goal but at least 1% further reduction. Age and dosing limits must still be met.

Not covered when

Concurrent DPP-4 inhibitor use
Type 1 diabetes

Policy note: Mounjaro (tirzepatide) is classified as a GIP/GLP-1 receptor agonist in Table 1. It is listed only for glycemic control in T2DM in this policy; no CV, CKD, weight loss, or OSA indications are listed. Zepbound (tirzepatide for weight loss/OSA) is NOT mentioned in this document. The policy is specific to Type 2 Diabetes Mellitus agents only.

Policy effective April 16, 2025 · verified June 4, 2026 · source: Diabetes-Mellitus-Type-2-Agents-PDF

Why Mounjaro requests get denied by Kansas Medicaid

Based on what this policy asks for. Fix these before the first submission.

Wrong brand for the diagnosis. Mounjaro and Zepbound are the same molecule with different approved uses; a request for Mounjaro under a diagnosis that matches Zepbound is routinely denied.
No documented metformin trial (dose, dates, and outcome) or a stated reason it can't be used.

Frequently asked questions

Does Kansas Medicaid cover Mounjaro?: Kansas Medicaid covers Mounjaro for type 2 diabetes with prior authorization on Medicaid.
Do you have to try metformin before Mounjaro?: Yes for type 2 diabetes: Kansas Medicaid requires a documented trial of metformin of at least 90 days, or a documented reason it can't be used (["contraindication", "combination_with_high_a1c"]).
How long does a Mounjaro approval last with Kansas Medicaid?: Initial approvals last 6 months.
What does Kansas Medicaid require to renew Mounjaro?: Improvement in A1C and Renewal requires either: (1) reduction of HbA1c of at least 1% since the last approval, OR (2) achievement or maintenance of therapeutic HbA1c goal as specified on the initial request. Renewal duration is 12 months if at HbA1c goal, or 6 months if not at goal but at least 1% further reduction. Age and dosing limits must still be met.
How current is this information?: This page reflects Kansas Medicaid's written policy as of April 16, 2025, last verified against the source document on June 4, 2026.

Other medications under Kansas Medicaid

Mounjaro coverage under other plans

All insurance plans · All medications

This page summarizes Kansas Medicaid's written prior-authorization policy. It is not a guarantee of coverage; plans vary by employer and benefit design. Verify with your plan before relying on it.